FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1239-1240 October 17, 1996 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

To the Editor: In a recent letter to the editor (May 16 issue),¹ Rogers raised questions about the cost effectiveness of treatment of hypercholesterolemia. His calculations were derived from the West of Scotland Coronary Prevention Study.² I propose that a more sober account of cost effectiveness is in order. There are three major issues concerning the use of cholesterol-lowering drugs to prevent coronary heart disease: efficacy, safety, and cost effectiveness. A recent cost analysis of the use of 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) in secondary prevention indicated a high degree of cost effectiveness.³ Costs were much lower than for many . . . [Full Text of this Article]

References

Related Letters:

Prevention of Coronary Heart Disease with Pravastatin
Rogers S., Samani N. J., de Bono D. P., Davis D. R., Shepherd J., Cobbe S. M., Ford I., The West of Scotland Coronary Prevention Study Group , Pedersen T. R.
Extract | Full Text  
N Engl J Med 1996; 334:1333-1335, May 16, 1996. Correspondence

This article has been cited by other articles:

• Pickin, D M, McCabe, C J, Ramsay, L E, Payne, N, Haq, I U, Yeo, W W, Jackson, P R (1999). Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 82: 325-332 [Abstract] [Full Text]